Fuhrman Alan
- SEC CIK
- 0001303521
No open-market purchases or sales filed in the past year.
Current role at each company
- TYRA Tyra Biosciences, Inc.Chief Financial Officeras of Sep 17, 2026
- SWTX SpringWorks Therapeutics, Inc.Directoras of Jul 2, 2025
- ESPR Esperion Therapeutics, Inc.Directoras of May 24, 2024
- CMPI Checkmate Pharmaceuticals, Inc.Directoras of May 31, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Fuhrman Alan as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
TYRA Tyra Biosciences, Inc.
Chief Financial Officer1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 1, 2024 (view filing) | Oct 30 | 2 days | Fuhrman AlanChief Financial Officer | PPurchase | +9.50K | $16.00 | +$152.0K | +283.7%12.8K after |